By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Beam Therapeutics Inc. has raked in $255 million in cash from the sale of its spinout, Orbital Therapeutics, to Bristol Myers ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
3don MSN
Outgoing GSK boss Emma Walmsley says US is 'best place to invest' in parting shot at UK pharma
GSK and UK-based rival AstraZeneca have revealed billions of dollars in US investment in recent months in response to ...
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...
hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...
Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback